KEYNOTE-522

Conference, ESMO 2023, Keytruda, Breast Cancer, LBA18, KEYNOTE-522

How Keytruda Improved Survival Outcomes for Early-Stage TNBC Patients: KEYNOTE-522 Trial

Anika Sharma

ESMO 2023: LBA18 Underpinning this approval is the seminal KEYNOTE-522 trial, a Phase III study that diverges from pre-2021 tactics ...